CIMZIA® (certolizumab pegol) label change marks important advance for European women of childbearing age with chronic inflammatory disease.

Brussels, Belgium – 9 January, 7:00 CEST – UCB today announced that the European Medicines Agency (EMA) approved a label change for CIMZIA ® (certolizumab pegol), making it the first anti-TNF treatment option that could be considered for women with chronic inflammatory disease, during both pregnancy and breastfeeding. “Women of childbearing age with chronic inflammatory disease are a patient population in need of reliable treatment options and guidance. Women frequently discontinue their anti-TNF treatment throughout pregnancy, a time when disease control is essential to ensure optimal infant...